Tci Wealth Advisors, Inc. Biomarin Pharmaceutical Inc Transaction History

Tci Wealth Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$87.74 - $117.27 $8,159 - $10,906	-93 Reduced 37.65%	154 $14,000
Q4 2022 Feb 06, 2023	BUY	$80.93 - $108.63 $8,093 - $10,863	100 Added 68.03%	247 $25,000
Q3 2022 Nov 08, 2022	BUY	$82.16 - $96.94 $575 - $678	7 Added 5.0%	147 $12,000
Q1 2022 Apr 29, 2022	SELL	$74.28 - $92.69 $2,748 - $3,429	-37 Reduced 20.9%	140 $11,000
Q4 2021 Jan 24, 2022	BUY	$71.72 - $91.47 $1,075 - $1,372	15 Added 9.26%	177 $16,000
Q2 2021 Aug 02, 2021	BUY	$75.51 - $84.79 $2,265 - $2,543	30 Added 22.73%	162 $14,000
Q1 2021 Apr 29, 2021	BUY	$74.73 - $90.69 $5,380 - $6,529	72 Added 120.0%	132 $10,000
Q2 2017 Aug 10, 2017	BUY	N/A	60	60 $5,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.